Acadia Pharmaceuticals price target has been raised from $17 to $19 at Oppenheimer
Oppenheimer grew the company’s Price target About Acadia’s medicines (Academy) Maintains a performance rating for the stock from $17 to $19. The company considers the Delaware court verdict in line with Nuplazid’s expectations for intellectual property protection, in favour of Acadia, removing perceived overhangs in stock. The court specifically concluded that Acadia was demonstrated by the predominance of evidence that Aurobindo infringes patent claims, analysts told investors in a research note. OPCO expects investors’ focus to return to key dynamics following the Q1 update, following the R&D date on June 25th.
First published fly – The ultimate source of financial news that moves to the market in real time. Try it now >>
See the best stocks recommended by Analyst >>
Read more about Acad: